<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040534</url>
  </required_header>
  <id_info>
    <org_study_id>P01499</org_study_id>
    <nct_id>NCT00040534</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of an oral Farnesyl&#xD;
      Protein Transferase&#xD;
&#xD;
      Inhibitor (SCH 66336) when given in combination with Gemcitabine and Cisplatin in patients&#xD;
      with advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">22</enrollment>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Farnesyl Protein Transferase Inhibitor</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced cancer for which there is no treatment available which would have a&#xD;
             reasonable chance of disease palliation or cure&#xD;
&#xD;
          -  Age greater than or equal to 18.&#xD;
&#xD;
          -  SWOG performance Status less than or equal to 2.&#xD;
&#xD;
          -  Meets protocol requirements for specified laboratory values.&#xD;
&#xD;
          -  Written informed consent and cooperation of patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with an FPTI&#xD;
&#xD;
          -  Knowledge of intracranial metastases or carcinomatous meningitis.&#xD;
&#xD;
          -  Poor medical risks because of nonmalignant systemic disease or uncontrolled active&#xD;
             infection.&#xD;
&#xD;
          -  Medical conditions that would interfere with taking oral medications.&#xD;
&#xD;
          -  Significant uncontrolled diarrhea.&#xD;
&#xD;
          -  Chemotherapy, radiotherapy or major surgery within 4 weeks; full recovery from prior&#xD;
             treatment.&#xD;
&#xD;
          -  Concomitant use of CYP3A inhibitors/inducers per protocol.&#xD;
&#xD;
          -  Known HIV positivity or AIDS-related illness.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Men or women of childbearing potential who are not using an effective method of&#xD;
             contraception.&#xD;
&#xD;
          -  Concurrent chemotherapy, hormonal therapy, radiotherapy or immunotherapy.&#xD;
&#xD;
          -  QTc prolongation (&gt;440 msecs) at baseline.&#xD;
&#xD;
          -  Patients with previous high-dose therapy requiring stem cell rescue or bone marrow&#xD;
             transplant, or irradiation to &gt;30% of bone marrow-containing areas.&#xD;
&#xD;
          -  Patients that have received Mitomycin-C or nitrosoureas.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Sep;62(4):631-46. Epub 2007 Dec 6.</citation>
    <PMID>18058098</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>June 28, 2002</study_first_submitted>
  <study_first_submitted_qc>June 28, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2002</study_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

